Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 7.4 0.00% 0.00
FENC closed up 1.09 percent on Friday, May 29, 2020, on 26 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical FENC trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.07%
Outside Day Range Expansion 2.07%
Down 3 Days in a Row Weakness 2.07%
Narrow Range Bar Range Contraction 1.93%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Biopharmaceutical Cancer Disease Oncology Brain Tumor Cancer Therapeutics Neuroblastoma Hearing Loss Osteosarcoma Neoplasms Localized Tumors

Is FENC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.4
52 Week Low 3.255
Average Volume 115,171
200-Day Moving Average 5.91
50-Day Moving Average 6.66
20-Day Moving Average 7.08
10-Day Moving Average 7.39
Average True Range 0.49
ADX 18.38
+DI 21.69
-DI 16.02
Chandelier Exit (Long, 3 ATRs ) 6.50
Chandelier Exit (Short, 3 ATRs ) 7.41
Upper Bollinger Band 7.89
Lower Bollinger Band 6.26
Percent B (%b) 0.7
BandWidth 23.04
MACD Line 0.20
MACD Signal Line 0.19
MACD Histogram 0.0065
Fundamentals Value
Market Cap 116.67 Million
Num Shares 15.8 Million
EPS -0.29
Price-to-Earnings (P/E) Ratio -25.52
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.76
Resistance 3 (R3) 7.75 7.62 7.70
Resistance 2 (R2) 7.62 7.53 7.63 7.68
Resistance 1 (R1) 7.51 7.47 7.57 7.52 7.66
Pivot Point 7.38 7.38 7.41 7.39 7.38
Support 1 (S1) 7.27 7.29 7.33 7.28 7.14
Support 2 (S2) 7.14 7.23 7.15 7.12
Support 3 (S3) 7.03 7.14 7.10
Support 4 (S4) 7.04